Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 32, 2024 - Issue 4
Submit an article Journal homepage
177
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Peripheral Ulcerative Keratopathy following Systemic Treatment with Bortezomib: A Case Report

Javier Avilés-Prietoa Department of Ophthalmology, University Hospital Virgen Macarena, Seville, SpainView further author information
, MD,
Manuel Caro-Magdalenoa Department of Ophthalmology, University Hospital Virgen Macarena, Seville, Spain;b Members of RETICS OFTARED RD16/0008/0010 and RICORS FISS-21-RD21/0002/0011 (Inflammatory Diseases Network, Ocular Inflammatory Diseases, Ocular Surface Inflammatory Non Infectious Diseases, Instituto de Salud Carlos III);c Department of Surgery, Ophthalmology Area, University of Seville, Seville, SpainCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4922-027XView further author information
, MD, PhDORCID Icon &
Enrique Rodríguez-de-la-Rúa-Francha Department of Ophthalmology, University Hospital Virgen Macarena, Seville, Spain;b Members of RETICS OFTARED RD16/0008/0010 and RICORS FISS-21-RD21/0002/0011 (Inflammatory Diseases Network, Ocular Inflammatory Diseases, Ocular Surface Inflammatory Non Infectious Diseases, Instituto de Salud Carlos III);c Department of Surgery, Ophthalmology Area, University of Seville, Seville, SpainView further author information
, PhD
Pages 470-472 | Received 22 Mar 2022, Accepted 22 Jan 2023, Published online: 13 Feb 2023

References

  • Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372(10):944–953. doi:10.1056/NEJMoa1412096.
  • Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström macroglobulinemia. Am J Hematol. 2010;85(9):670–674. doi:10.1002/ajh.21788.
  • Troch M, Jonak C, Müllauer L, et al. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica. 2009;94(5):738–742. doi:10.3324/haematol.2008.001537.
  • Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(27):4293–4297. doi:10.1200/JCO.2007.11.4207.
  • Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer, part II: targeted therapy. J Am Acad Dermatol. 2014;71(2):217.e1–217.e11; quiz 227. doi:10.1016/j.jaad.2014.04.013.
  • Min CK, Lee S, Kim YJ, et al. Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines. Eur J Haematol. 2006;76(3):265–268. doi:10.1111/j.0902-4441.2005.t01-1-EJH2437.x.
  • Fraunfelder FW, Yang HK. Association between bortezomib therapy and eyelid chalazia. JAMA Ophthalmol. 2016;134(1):88–90. doi:10.1001/jamaophthalmol.2015.3963. PMID: 26469392.
  • Sklar BA, Gervasio KA, Leng S, Ghosh A, Chari A, Wu AY. Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case series. BMC Ophthalmol. 2019;19(1):110. doi:10.1186/s12886-019-1118-x. PMID. PMCID: PMC6518763.
  • Grob SR, Jakobiec FA, Rashid A, Yoon MK. Chalazia associated with bortezomib therapy for multiple myeloma. Ophthalmology. 2014;121(9):1845–7.e3. doi:10.1016/j.ophtha.2014.04.021.
  • Dennis M, Maoz A, Hughes D, Sanchorawala V, Sloan JM, Sarosiek S. Bortezomib ocular toxicities: outcomes with ketotifen. Am J Hematol. 2019;94(3):E80–E82. doi:10.1002/ajh.25382. Epub January 3 2019. PMID: 30575098.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.